Are Combinations the Solution: Perspectives on Combination Immunotherapy

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Immunotherapy: Paradigm on the Rise

MOA of Inhibitors on PD-1 Pathway

FDA Approved PD-1/PD-L1 Inhibitors

Toxicity With PD-1/PD-L1 Inhibitors

Predictive Biomarkers Are Lacking

PD-1 and CTLA-4 Inhibition in Melanoma

CheckMate 069

What About Other Tumors?

CheckMate 012

Durvalumab/Tremelimumab in NSCLC

Toxicity in a Broader Population

Immunotherapy Is Not Chemotherapy

Immunotherapy/Immunotherapy Summary

Chemoimmunotherapy

KEYNOTE 021

KEYNOTE 024

Chemotherapy/Immunotherapy Summary

Overcoming Challenges of Targeted Therapies

PD-1/BRAF/MEK Inhibition in Melanoma

PD-1/EGFR Inhibition in NSCLC

TATTON Results: EGFR/PD-L1 Inhibition

Is Immunotherapy the Right Approach?

Mutational Load in Never Smokers

Targeted Therapy/Immunotherapy Summary

Overall Conclusions

Abbreviations